Bindu Donovan spoke on a panel, “Charting the Evolving Boundaries of the Safe Harbor Defense to Patent Infringement: Activities 'Reasonably Related' to FDA Approval", at the 14th Annual Summit on Biosimilars & Innovator Biologics, hosted by the American Conference Institute.
The ACI's Biosimilars and Innovator Biologics summit brings together industry leaders, policymakers, and innovators to tackle challenges, uncover strategies, and drive innovation, accessibility, and success in the evolving biosimilars market.
For more details on the summit, visit the website.
